Previous Article | Next Article ![]()
Molecular and Cellular Biology, December 2006, p. 8743-8754, Vol. 26, No. 23
0270-7306/06/$08.00+0 doi:10.1128/MCB.02251-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
,
Department of Molecular Genetics, Microbiology, and Immunology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, New Jersey 08854,1 Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, 108 N. Greene St., Baltimore, Maryland 212012
Received 22 November 2005/ Returned for modification 12 December 2005/ Accepted 1 September 2006
|
|
|---|
|
|
|---|
5' deadenylation, followed by degradation of the mRNA body (25, 58).
Both the turnover kinetics and translational efficiency of ARE-containing mRNAs may be regulated through the activity of cellular ARE-binding proteins. Over the past 15 years, a variety of these factors have been identified, including AUF1 [ARE- and poly(U)-binding and degradation factor 1], BRF1 (butyrate response factor 1), Hsc/Hsp70, the Hu family of proteins (HuR, HuB, HuC, and HuD), KSRP (KH domain splicing regulatory protein), PM-Scl75 (polymyositis-scleroderma overlap syndrome 75-kDa antigen), TIA-1 (T-cell internal antigen 1), TIAR (TIA-1-related protein), and tristetraprolin (TTP) (2, 8, 58). AUF1, also known as hnRNP D, was first identified by its ability to promote degradation of c-myc mRNA in a cell-free mRNA decay system (7, 56). mRNP immunoprecipitation and microarray analyses indicated that AUF1 binds to ARE-containing mRNAs encoding many cytokines, oncoproteins, cell cycle regulators, and G protein-coupled receptors (34). Small interfering RNA (siRNA)-mediated depletion of AUF1 stabilizes ARE-containing mRNAs, including those for GADD45
, cyclin D1, and the cell cycle inhibitors p21 and p16INK4a, and a reporter mRNA containing the interleukin-3 ARE (33, 34, 49). In addition to its role in AMD, AUF1 participates in other cellular processes, including telomere maintenance and transcriptional activation/repression (12, 14, 16, 18, 20, 26).
AUF1 is expressed as a family of four protein isoforms generated by alternative splicing of a common pre-mRNA (13, 15, 30, 54). While the AUF1/HNRPD gene consists of 10 exons, the translational termination codon lies in exon 8 rather than the 3'-terminal exon, which is the case for most mRNAs (13, 48, 54). As such, the unusual 3'-end structure of the AUF1/HNRPD gene presents the opportunity for multiple pre-mRNA splicing patterns, potentially creating transcripts with five distinct 3'-UTR structures (Fig. 1) (also see reference 57). In earlier work, we identified four of these AUF1 3'-UTR splice variants (I, II, IV, and V) (Fig. 1) in the human chronic myelogenous leukemia cell line K562 (57). Two observations further suggested that these alternative 3'-UTR structures could play a role in regulating AUF1 expression. First, these transcripts are polysome associated, suggesting that they are not simply inactive nuclear by-products of inefficient pre-mRNA splicing. Second, the 107-nucleotide (nt) exon 9 is 100% conserved between the mouse and human AUF1 loci, while the 3' 130 nt of intron 8 and the 5' half of intron 9 retain 99% identity between these species. The extreme conservation of these untranslated mRNA sequences present in variants II, III, and IV suggests that they have critical, albeit unknown, functions in regulating AUF1 expression, which may include control of mRNA translation, stability, or subcellular localization (11). Our earlier work also suggested two mechanisms by which 3'-UTR sequences could regulate levels of specific splice variants (57). First, intron 9, which is present in splice variants IV and V, contains two AUF1-binding sites that could target these transcripts for degradation by AMD. Second, selective excision of intron 9, generating variants II and III, would position an exon-exon junction >50 nt downstream of the stop codon, which may target these transcripts for degradation by the nonsense-mediated mRNA decay (NMD) pathway (48).
![]() View larger version (17K): [in a new window] |
FIG. 1. Potential splicing variants of the AUF1 3'-UTR. Five possible AUF1 3'-UTR splice variants are shown based upon the exon-intron organization of the AUF1 gene. Arrows below the diagrams of variant mRNAs I to IV depict the locations of forward and reverse primers for qRT-PCR amplification of each specific splice variant.
|
3' exonucleolytic decay of the transcript (23). A similar pathway may function in mammalian cells as well, but there is evidence that accelerated deadenylation is also involved (9, 39, 59). A major mechanism by which mammalian cells distinguish a bona fide translational termination codon from a PTC is the position of the stop codon in relation to an exon-exon junction in an mRNA molecule; stop codons located >50 nt upstream of an exon-exon junction normally trigger NMD (27, 44, 48), although T-cell receptor transcripts appear to be exceptions to this rule (41). In the nucleus, pre-mRNA splicing leads to the deposition of the exon junction protein complex 20 to 24 nt upstream of each exon-exon junction. The exon junction protein complex serves as a platform for the binding of Upf3/Upf3X and Upf2 (36-38). Upf2 recruits Upf1, an ATP-dependent 5'-to-3' RNA helicase and ATPase (4, 46, 52). The nuclear cap-binding proteins CBP20-CBP80 associate with the 5' cap, and the poly(A)-binding protein PABP2 associates with the 3' poly(A) tract (28). The mRNP complex then undergoes a pioneer round of translation that establishes whether the mRNA contains a PTC (10, 29). Subsequent remodeling of the protein constellation of the mRNP then permits either mRNA degradation for nonsense-containing transcripts or additional rounds of translation for normal transcripts (10, 21, 29, 40). Given the unusual 3'-end structure of the AUF1 gene and our prior work demonstrating that alternative pre-mRNA splicing permits the expression of highly conserved 3'-UTR elements (intron 8, exon 9, and intron 9) in AUF1 mRNA, we predicted that NMD might control the expression of selected AUF1 3'-UTR splice variants. In this study, we show that disruption of the NMD pathway, either by reduction of human Upf1 or Upf2 or by expression of a dominant-negative Upf1 mutant, enhances the expression of selected 3'-UTR splice variants of AUF1 mRNA involving transcript stabilization and that Upf1 and Upf2 can associate with an NMD-responsive AUF1 mRNA in cells. Finally, we demonstrate that AUF1 3'-UTR variant mRNAs are differentially expressed during murine embryogenesis, which may impact the spatiotemporal expression of AUF1 during development and ultimately provide a model system for defining the functional and gene regulatory consequences of alternative pre-mRNA splicing events in the AUF1 3'-UTR.
|
|
|---|
Cell culture and transfections. The human cervical carcinoma cell line HeLa was grown in Dulbecco's modified Eagle medium (Gibco BRL) containing 10% fetal bovine serum (HyClone) supplemented with L-glutamine, penicillin, and streptomycin at 37°C with 5% CO2. For transfections, 1.5 x 105 cells per well were plated in a six-well plate and cultured overnight. The next day, siRNAs were transfected at a final concentration of 100 nM in the presence of serum-free medium (OptiMEM; Invitrogen), using Lipofectamine 2000 (Invitrogen). Analyses of endogenous mRNA and protein expression were performed 72 h after transfection. In two-hit transfection experiments, a second round of siRNA transfection was performed 24 h after the first round. Where indicated, a plasmid carrying either a Upf1 or Upf2 siRNA-resistant cDNA (22, 31) was cotransfected with the second siRNA application. These plasmids contain silent nucleotide exchanges within the sequences to which the respective siRNAs anneal, thus making the encoded mRNAs refractory to RNA interference (RNAi).
The construction of plasmids expressing firefly luciferase-AUF1 3'-UTR chimeric mRNAs downstream of the simian virus 40 core promoter was described previously (57). For experiments utilizing luciferase-AUF1 3'-UTR constructs, HeLa cells were transfected 48 h after siRNA transfection with 1 µg of firefly luciferase reporter plasmid/well and 10 ng/well control Renilla luciferase vector pRL-SV40 (Promega), using Lipofectamine 2000. Where indicated, HeLa cells were cotransfected with 200 ng of either pCI-neo-hUPF1 or pCI-neo-hUPF1(R844C), encoding wild-type (wt) Upf1 or a helicase-defective mutant of Upf1, respectively (52). Preparation of RNA and protein samples for downstream analyses was performed at 48 h posttransfection. Where indicated, firefly luciferase activity was measured using a dual-luciferase kit (Promega), with Renilla luciferase activity as an internal control.
Western blot analyses. Two million cells per 60-mm dish were resuspended in 0.25 ml of polysome lysis buffer (100 mM KCl, 50 mM MgCl2, 10 mM HEPES [pH 7.9], 0.5% NP-40, 0.1 mM dithiothreitol, and 1x protease inhibitor cocktail [Roche] [7x protease inhibitor cocktail = one tablet dissolved in 1.5 ml deionized water]). The suspension was incubated on ice for 15 min and centrifuged at 4°C for 30 min at 12,000 x g to pellet nuclei and cell debris. The protein concentrations of cytoplasmic supernatants were determined by the Bradford assay, using bovine serum albumin standards.
For Western blot analyses, cytoplasmic proteins (30 to 50 µg) were size fractionated by 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Fisher). To detect Upf1 or Upf2, membranes were incubated with polyclonal goat antibodies (1:300; Santa Cruz) followed by rabbit anti-goat immunoglobulin G (IgG)-horseradish peroxidase conjugate (1:5,000; Promega). Immunoreactive bands were detected using a SuperSignal West Pico chemiluminescent substrate kit (Pierce) and exposure to X-ray film. For normalization, blots were reincubated with a mouse monoclonal antibody to
-tubulin (1:10,000; Sigma) followed by goat anti-mouse IgG-horseradish peroxidase conjugate (1:3,000; Promega) and were visualized by chemiluminescence detection. Western blot data were quantified by scanning multiple film exposures using a DC120 Zoom digital image system (Kodak).
qRT-PCR. Purified total RNA was incubated with RNase-free DNase I (Roche) to remove any contaminating DNA, repurified using an RNeasy kit (QIAGEN), and quantified spectrophotometrically by measuring the A260. One-step quantitative reverse transcription-PCR (qRT-PCR) was performed using SYBR green, a Taqman reverse transcription kit (Applied Biosystems), and an Mx4000 multiplex quantitative PCR system (Stratagene, La Jolla, CA). Primer sets for each mRNA were designed using Primer-3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and were synthesized by Integrated DNA Technologies. The sequences of all qRT-PCR primer sets are displayed in Table S1 in the supplemental material. For quantitation of specific endogenous mRNAs, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was used as an internal control. Renilla luciferase mRNA was used as a standardization control in luciferase cotransfection experiments.
qRT-PCR mixtures were assembled in triplicate in a final volume of 50 µl containing sense and antisense primers (50 pmol each). The reverse transcription reaction was performed at 48°C for 30 min, and then the reverse transcriptase was inactivated at 95°C for 10 min. The PCR cycles were as follows: 40 cycles of 95°C for 15 s, 52°C for 1 min, and 68°C for 2 min. Single-fragment amplification by each qRT-PCR primer set was verified by thermal denaturation and 3% agarose gel electrophoresis. Reaction mixtures lacking template or reverse transcriptase were used as negative controls. Data were analyzed by the 
CT method, using software provided with the Mx4000 system (Strategene), and are presented as means ± standard deviations (SD) for at least three independent experiments.
mRNP immunoprecipitation. Twenty million HeLa cells in a 150-mm plate were cotransfected with plasmid pFLAG, pFLAG-Upf1, or pT7-Upf2 (3 µg), together with a luciferase expression vector (1 µg) lacking (pGL3-Promoter) or containing the spliceable AUF1 exon 9-intron 9-exon 10 cassette (pGL3-Ex9:In9:Ex10). Two days after transfection, cells were released with trypsin, pelleted, and washed twice with ice-cold phosphate-buffered saline (PBS). The cell pellet was resuspended in an equal volume of polysome lysis buffer (described above) supplemented with 40 U/ml RNasin and 40 µl of 7x protease inhibitor cocktail (described above). Cells were disrupted by sonication, and debris was removed by centrifugation at 10,000 x g for 30 min at 4°C. The lysates were precleared by incubation with 30 µl of normal mouse serum and protein A-Sepharose beads for 45 min at 4°C. The precleared lysates were then fractionated by mRNP immunoprecipitation as described previously (29), using protein A-Sepharose beads preloaded with either mouse IgG, anti-FLAG antibody (Sigma), or anti-T7-tag antibody (Novagen). Proteins retained in antibody-bead pellets were analyzed for FLAG-Upf1 or T7-Upf2 by Western blotting using antibodies directed at each epitope tag, as well as anti-Upf1 and anti-Upf2 antibodies. RNAs retained in antibody-bead pellets were analyzed for firefly luciferase mRNA by RT-PCR. Amplified DNA products were resolved by electrophoresis through 1.5% agarose gels and visualized by ethidium bromide staining.
mRNA decay assays. Seventy-two hours after being transfected with control, Upf1, or Upf2 siRNA, HeLa cells were treated with 5,6-dichloro-1-ß-D-ribofuranosylbenzimidazole (DRB) to inhibit polymerase II (Pol II) transcription (47). At selected time points thereafter, total RNA was extracted using Trizol reagent (Invitrogen). Levels of AUF1 mRNA splice variants were quantified at each time point by qRT-PCR and were normalized to GAPDH mRNA levels. First-order decay constants (k) and associated mRNA half-lives were calculated from plots of percent AUF1 variant mRNA remaining versus time of DRB treatment, using Prism 3.03 software (GraphPad).
Mouse embryos. All animal protocols were approved by the Institutional Animal Care and Use Committee of Robert Wood Johnson Medical School. Matings between C57BL/6 mice were timed, and pregnant females were sacrificed at various days postcoitum. Embryos at selected developmental stages (E5.5, E9.5, E13.5, and E16.5) were dissected from the uterus, and extra-embryonic membranes were removed. Embryos were rinsed in PBS and either fixed in 4% paraformaldehyde in PBS overnight at 4°C or frozen in liquid nitrogen following a PBS wash. Total RNA from each embryo was extracted using an RNeasy kit (QIAGEN). Total RNA was then incubated with RNase-free DNase I (Roche) to remove genomic DNA and repurified using an RNeasy kit. RNA yields were determined by measuring the A260, and integrity was verified by 1% agarose gel electrophoresis.
Statistical analyses. Quantitative comparisons between data sets were performed using the unpaired two-tailed t test (PRISM v3.03), with P values of <0.05 considered significant.
|
|
|---|
137 nt upstream of the exon 9-exon 10 junction, these mRNA products were predicted to be NMD targets. To test this hypothesis, changes in the expression of AUF1 mRNA splice variants were evaluated following siRNA-directed reduction of Upf1, a central component of the cellular NMD machinery. A single-hit Upf1 siRNA transfection protocol yielded a 65 to 70% decrease in Upf1 protein levels over 72 h relative to those in cells transfected with a control siRNA (data not shown), while a two-hit siRNA transfection strategy reduced Upf1 to undetectable levels (Fig. 2A). Extended film exposures and comparisons against an immunoblot containing a titration of lysate (Fig. 2A, left panel) indicate that Upf1 levels were reduced >90% by the two-hit siRNA transfection. A similarly dramatic siRNA-dependent repression of Upf1 mRNA (Fig. 2B) was consistent with the reduction in Upf1 protein levels.
![]() View larger version (15K): [in a new window] |
FIG. 2. Effects of Upf1 reduction on expression of endogenous AUF1 3'-UTR splice variants. (A) Western blot analysis of Upf1 levels. A two-hit strategy was used to transfect control or Upf1-specific siRNA into HeLa cells. A parallel culture was cotransfected with a plasmid encoding an siRNA-resistant Upf1 cDNA (Upf1R) and Upf1 siRNA as described in Materials and Methods. A twofold dilution series of HeLa cytoplasmic lysate was probed with antibodies for Upf1 and -tubulin to permit estimations of the Upf1 knockdown efficiency (left). Estimates of Upf1 protein levels in the cytoplasm of transfected cells are expressed as percentages of Upf1 in cells transfected with control siRNA (right). n.d., not detectable. (B) qRT-PCR analysis of changes in Upf1 mRNA levels resulting from two-hit transfection of Upf1 siRNA, with or without cotransfected Upf1R, relative to control siRNA transfection, expressed as means ± SD (n = 3). **, P < 0.01 versus control siRNA. (C) Upf1-dependent changes in expression of endogenous AUF1 3'-UTR splice variants. Total RNA was isolated from the transfected cells described in panel A or from cells transfected with a single hit of Upf1 siRNA and analyzed by qRT-PCR, using primer pairs specific for individual AUF1 3'-UTR splice variants (see Fig. 1). The bars indicate the means ± SD (n = 4), where the level of each AUF1 variant mRNA is relative to that measured in cells transfected with the control siRNA (dotted line) **, P < 0.01 versus control siRNA. The same RNA samples were utilized to perform the qRT-PCRs shown in panels B and C.
|
3'-UTR elements mediate control of AUF1 mRNA splice variant expression by Upf1. To define elements within AUF1 mRNA required for Upf1-dependent regulatory control, we tested whether selected regions of the AUF1 3'-UTR could confer Upf1-dependent expression on a luciferase reporter gene. Previous work showed that no sequence in either exon 8, 9, or 10 significantly influenced luciferase reporter expression in HeLa cells (57). However, inclusion of intron 9 sequences together with intact 5' and 3' splice sites (to permit intron 9 splicing) reduced reporter gene expression at both the protein and mRNA levels. Since the stop codon is >50 nt upstream of the resulting junction between exons 9 and 10, we predicted that this Ex9:In9:Ex10 transcript could be a substrate for the NMD pathway.
siRNA-directed reduction of Upf1 increased levels of the pGL3-Ex9:In9:Ex10 reporter mRNA 2.5-fold (Fig. 3, construct 2, middle panel) and increased luciferase reporter activity 3-fold (Fig. 3, construct 2, right panel) compared to those in cells transfected with the control siRNA. These results are consistent with elevated expression of endogenous AUF1 mRNA splice variants II and III following Upf1 knockdown (Fig. 2C), since both of these mRNAs also contain a splice junction between exons 9 and 10 (Fig. 1). By contrast, expression of the pGL3-Promoter reporter was not influenced at either the mRNA or protein level by transfection of either control or Upf1 siRNA (Fig. 3), verifying that sequence elements in the AUF1 3'-UTR are required for Upf1-dependent regulatory control. The influence of Upf1 on the expression of luciferase-AUF1 3'UTR chimeric mRNAs also required intron 9 splicing, since deletion of the 3' splice site abrogated Upf1 siRNA-dependent changes in reporter mRNA levels (Fig. 3, construct 3, middle panel). Interestingly, however, Upf1 knockdown reduced expression from pGL3-Ex9:In9 by 80% at the protein level compared to that in the presence of the control siRNA (Fig. 3, construct 3, right panel). This result suggests that, at least under some conditions, Upf1 may contribute to the translational efficiency of some mRNAs (see Discussion).
![]() View larger version (16K): [in a new window] |
FIG. 3. Identification of AUF1 3'-UTR elements required for regulation by Upf1. Schematics of firefly luciferase-AUF1 3'-UTR chimeric mRNAs are shown on the left and are numbered for text reference. AUF1 exon and intron sequences are labeled, and the ABS within intron 9 are indicated by a black box. In constructs where intron 9 cannot be excised by splicing, the intron sequence is shaded. HeLa cells were first transfected with control or Upf1-specific siRNA, followed 48 h later by cotransfection of luciferase-AUF1 3'-UTR constructs and a Renilla luciferase control vector. Two days following luciferase transfections, firefly and Renilla luciferase mRNA and activity levels were measured as described in Materials and Methods. For each chimeric mRNA, bars represent the means ± SD (n = 3) of firefly luciferase mRNA levels (middle panel) or activities (right panel) relative to those for the control siRNA transfection following normalization to Renilla luciferase mRNA and activity, respectively. *, P < 0.05; **, P < 0.01 versus control siRNA.
|
ABS). Similar to the case with the Ex9:In9:Ex10 chimera, Upf1 knockdown significantly enhanced expression of the
ABS reporter at both the mRNA and protein levels (Fig. 3, cf. constructs 2 and 4), indicating that Upf1-mediated repression of these mRNA substrates does not require the AUF1-binding sites.
Taken together, these data are consistent with a model whereby removal of intron 9 by pre-mRNA splicing is necessary and sufficient for suppression of AUF1 mRNA splice variants II and III by Upf1. However, subsequent experiments using an independent method for disrupting cellular Upf1 function were performed to validate these findings. In these experiments, the expression of selected luciferase-AUF1 3'-UTR chimeric mRNAs was evaluated in the presence of ectopically expressed wild-type Upf1 or a mutant containing an Arg
Cys substitution in the helicase domain (R844C). The Upf1 R844C mutant displays dominant-negative activity in cells and has been reported to modestly (approximately twofold) increase the levels of mRNAs containing PTCs (52).
As expected, coexpression of wt Upf1 or Upf1(R844C) did not exert any significant effect on expression from the plasmid pGL3-Promoter, which lacks any AUF1 sequences (Fig. 4). Overexpression of Upf1(R844C) increased luciferase mRNA levels approximately 2.5-fold from reporter chimeras containing the spliceable AUF1 intron 9, regardless of the presence (Ex9:In9:Ex10) or absence (Ex9:In9:Ex10
ABS) of the AUF1-binding sites (Fig. 4, constructs 2 and 4, middle panel, black bars). By contrast, cotransfection of wt Upf1 had no significant effect on expression of the Ex9:In9:Ex10 and Ex9:In9:Ex10
ABS chimeric mRNAs (Fig. 4, constructs 2 and 4, middle panel, gray bars). Luciferase activities from these reporter constructs were modestly (40 to 60%) but significantly (P < 0.05) enhanced by cotransfection of wt Upf1 (Fig. 4, constructs 2 and 4, right panel, cf. gray and white bars). However, expression of Upf1(R844C) induced much more dramatic (2.5- to 3-fold) increases in luciferase activity from reporter chimeras containing the spliceable intron 9 (Fig. 4, constructs 2 and 4, right panel, black bars), indicating that expression of the putative NMD substrate mRNAs was more profoundly influenced by the dominant-negative than wild-type Upf1. Similar to the Upf1 siRNA data (Fig. 3), cotransfection of either wild-type or dominant-negative Upf1 had no significant effect on expression of the splicing-defective Ex9:In9 reporter mRNA (Fig. 4, construct 3, middle panel). Together, these data demonstrate that intron 9 splicing is required for the regulation of luciferase-AUF1 3'-UTR reporter mRNAs by Upf1. Furthermore, a specific role for Upf1 in restricting the expression of these candidate NMD substrate mRNAs is supported by the enhanced reporter mRNA levels observed concomitant with either siRNA-mediated reduction of endogenous Upf1 (Fig. 3) or coexpression of a dominant-negative Upf1 mutant (Fig. 4).
![]() View larger version (16K): [in a new window] |
FIG. 4. Control of luciferase-AUF1 3'-UTR splice variant expression by a dominant-negative Upf1 mutant. Schematics of firefly luciferase-AUF1 3'-UTR chimeric mRNAs are shown as described in the legend to Fig. 3 (left). HeLa cells were cotransfected with luciferase-AUF1 3'-UTR constructs and a Renilla luciferase control vector in the absence (white bars) or presence of an expression vector encoding wild-type Upf1 (gray bars) or the dominant-negative Upf1 R844C mutant (black bars). At 2 days posttransfection, firefly and Renilla luciferase mRNA and activity levels were analyzed as described in Materials and Methods. For each reporter construct, bars represent the means ± SD (n = 3) of firefly luciferase mRNA levels (middle panel) or activities (right panel) relative to those for cotransfections lacking ectopic Upf1 (or the R844C mutant) following normalization to Renilla luciferase mRNA and activity, respectively. *, P < 0.05; **, P < 0.01 versus control.
|
Upf2 regulates expression of selected AUF1 3'-UTR splice variant mRNAs. Recent studies indicated that the stability of some mRNAs can be regulated by Upf1 independently of NMD. For example, the protein Staufen can recruit Upf1 to the 3'-UTR of ADP-ribosylation factor 1 (Arf1) mRNA to promote its degradation in an NMD-independent fashion (31). Thus, to validate a transcript as a bona fide NMD substrate, it is necessary to examine the influence of a second essential effector of NMD, such as Upf2 (31, 47).
To determine whether Upf2 also contributes to the regulated expression of selected AUF1 3'-UTR splice variant mRNAs, HeLa cells were transfected with either control or Upf2-specific siRNA, using a one-hit or two-hit protocol. At 72 hours posttransfection, the two-hit siRNA strategy decreased endogenous Upf2 protein levels by 54% and Upf2 mRNA by 75% relative to those in control siRNA transfections (Fig. 5A and B). A single-hit siRNA transfection reduced Upf2 protein levels <50% (data not shown). AUF1 splice variant-specific qRT-PCR analyses revealed that levels of AUF1 mRNA variants II and III were elevated >3-fold following Upf2 knockdown by two-hit siRNA transfection (Fig. 5C, gray bars), similar to the results observed in Upf1-depleted cells (Fig. 2C). Single-hit siRNA transfections were less effective in enhancing levels of AUF1 mRNA variants II and III (Fig. 5C, black bars), likely owing to the poor suppression of Upf2 expression possible by the one-hit approach. As expected, levels of AUF1 variant I and IV mRNAs, which are not predicted NMD substrates, were not significantly influenced by siRNA-directed knockdown of Upf2 expression. To control for potential off-target effects of the Upf2 siRNA, cells were cotransfected with two-hit Upf2 siRNA and a plasmid encoding siRNA-resistant Upf2 mRNA (Upf2R). Ectopic expression of Upf2R restored total cellular Upf2 protein (Fig. 5A, right panel) and mRNA (Fig. 5B) to near-normal levels and prevented the increased expression of AUF1 variant II and III mRNAs resulting from Upf2 siRNA transfection (Fig. 5C, white bars). Again, the levels of AUF1 variant I and IV mRNAs remained unaffected by manipulation of Upf2 expression. From this experiment, we conclude that suppression of cellular Upf2 levels is singularly responsible for the increased expression of AUF1 variant II and III mRNAs observed following transfection of Upf2 siRNA. Taken together, the data presented to this point indicate that both Upf1 and Upf2 play key roles in repressing the cellular expression of these AUF1 mRNA splice variants. As such, these results indicate that AUF1 3'-UTR variant II and III mRNAs are both bona fide substrates of the NMD pathway (44).
![]() View larger version (17K): [in a new window] |
FIG. 5. Effects
of Upf2 reduction on expression of endogenous AUF1 3'-UTR
splice variants. (A) Western blot analysis of Upf2 levels. A
two-hit strategy was used to transfect control or Upf2-specific siRNA
into HeLa cells or to cotransfect a combination of Upf2 siRNA and
siRNA-resistant Upf2 cDNA (Upf2R) as described in Materials
and Methods. Estimation of the Upf2 knockdown efficiency was performed
by probing immunoblots of cytoplasm from each transfected cell
population with antibodies for Upf2 and -tubulin (right panel)
and by comparison to a twofold dilution series of cytoplasmic lysate
from nontransfected HeLa cells (left panel). Estimates of Upf2 protein
levels in each cell population are expressed as percentages of the Upf2
in cells transfected with control siRNA. (B) Changes in Upf2
mRNA levels resulting from two-hit transfection of Upf2 siRNA, with or
without cotransfected Upf2R, relative to those with control
siRNA, measured by qRT-PCR and expressed as means ± SD
(n = 3). **, P < 0.01
versus control siRNA. (C) Upf2-dependent changes in
expression of endogenous AUF1 3'-UTR splice variants. Total RNA
was isolated from the transfected cells described in panel A or from
cells transfected with a single hit of Upf2 siRNA and analyzed for
individual AUF1 3'-UTR variant mRNAs by qRT-PCR. The bars
indicate the means ± SD (n = 4), where the
level of each mRNA variant is shown relative to that measured in cells
transfected with the control siRNA (dotted line). **,
P < 0.01 versus control siRNA. The same RNA samples
were utilized to perform the qRT-PCRs shown in panels B and
C.
|
![]() View larger version (15K): [in a new window] |
FIG. 6. Association
of Upf1 and Upf2 with AUF1 3'-UTR sequences.
(A) Analyses of Upf1 association. HeLa cells were transiently
transfected with plasmid pFLAG-Upf1 or a control vector lacking Upf1
sequences (pFLAG), together with luciferase reporter vectors lacking
(pGL3-Promoter) or containing (pGL3-Ex9:In9:Ex10) the AUF1 exon
9-intron 9-exon 10 sequence downstream of the luciferase coding region.
At 2 days posttransfection, whole-cell lysates were prepared and
fractionated by ribonucleoprotein immunoprecipitation (IP), using
anti-FLAG antibodies or control mouse IgG (mIgG) as described in
Materials and Methods. Immunoprecipitated material was analyzed by
Western blotting to validate anti-FLAG-dependent recovery of FLAG-Upf1
(top), while RT-PCR was used to identify copurifying firefly luciferase
mRNA (bottom). Lane 1 is a 100-bp ladder, and the position of the
500-bp marker is noted to the left of the panel. (B) Analyses
of Upf2 association. HeLa cells were cotransfected with plasmid
pT7-Upf2 and either pGL3-Promoter or pGL3-Ex9:In9:Ex10. Cell lysates
were prepared and immunoprecipitated, using control IgG or anti-T7-tag
antibody. Immunoprecipitated material was analyzed by Western blotting
for Upf2 and by RT-PCR for luciferase mRNA, essentially as described
for panel
A.
|
![]() View larger version (30K): [in a new window] |
FIG. 7. Decay
kinetics of endogenous AUF1 3'-UTR splice variants following
reduction of Upf1 or Upf2. The turnover rates of endogenous AUF1
3'-UTR variant I, II, III, and IV mRNAs were measured using DRB
time course assays following two-hit transfections of control (solid
circles, solid lines), Upf1 (open circles, dotted lines), or Upf2
(triangles, dashed lines) siRNA into HeLa cells. Levels of each AUF1
3'-UTR mRNA variant were normalized to that of GAPDH mRNA and
plotted as the percent AUF1 variant mRNA remaining as a function of
time following DRB treatment. Nonlinear regression analysis yielded
first-order decay constants (k) and associated cellular mRNA
half-lives, which are listed in Table
1.
|
|
View this table: [in a new window] |
TABLE 1. Decay kinetics of AUF1 3'-UTR variant mRNAs in control versus Upf1/Upf2-depleted HeLa cells
|
One situation where dynamic spatiotemporal patterns of AUF1 expression have been noted occurs during embryonic development. Gouble and Morello have reported variations in AUF1 protein expression between different tissues and as development progresses from stage E8.5 to adulthood (24). For example, at E10.5, AUF1 is expressed predominantly in the branchial arches, neural tube, and limb buds. By contrast, AUF1 levels in the brain are high between E10.5 and E16.5 but decline sharply thereafter. To test whether regulated expression of AUF1 3'-UTR variants might contribute to the dynamic changes in AUF1 levels observed during embryonic development, total RNAs were prepared from mouse embryos at E5.5, E9.5, E13.5, and E16.5 and analyzed for the expression of AUF1 3'-UTR variant mRNAs. Levels of both variant II and III mRNAs gradually increased as embryonic development proceeded from E5.5 to E16.5 (Fig. 8A and B). By contrast, the expression of AUF1 variant I mRNA did not change significantly between E5.5 and E16.5 (Fig. 8C). Enhanced levels of AUF1 variant II and III mRNAs in late murine development indicate that selected AUF1 3'-UTR variant mRNAs are expressed dynamically during embryogenesis. The potential significance of this novel regulatory event is considered below.
![]() View larger version (20K): [in a new window] |
FIG. 8. Dynamic expression of AUF1 3'-UTR splice variants during murine embryogenesis. Total RNA was purified from C57BL/6 embryos at developmental stages E5.5, E9.5, E13.5, and E16.5 as described in Materials and Methods. qRT-PCR was performed using RNAs from each developmental stage to quantify mRNA levels of AUF1 splice variant II (A), variant III (B), and variant I (C). Bars represent the means ± SD for levels of each AUF1 mRNA variant measured from four separate embryos at each stage, normalized to GAPDH mRNA and shown relative to the expression of each AUF1 variant mRNA at stage E5.5. *, P < 0.05; **, P < 0.01.
|
|
|
|---|
In the AUF1 3'-UTR, elements contained within intron 8, exon 9, and intron 9 are responsible for the control of AUF1 3'-UTR splice variant expression by NMD or AMD. Interestingly, within this domain there are sequences with extraordinarily strong conservation between the human and murine loci. Specifically, a 195-nt region roughly centered around exon 9 is 100% conserved between these species (57). Recent genomic analyses have identified 481 regions of at least 200 bp that are absolutely conserved (100% identity, with no insertions or deletions) between orthologous regions of the human and rodent genomes, which have been designated "ultraconserved elements" (3, 5, 6, 51). Moreover, the human and rodent genomes share 5,000 sequences with at least 100 bp of perfectly conserved sequence. Many of these ultraconserved elements overlap exons within genes that encode RNA processing factors or reside within introns or adjacent to genes that are involved in transcriptional control and development. While sequence conservation among genetic elements is a well-characterized indicator of functional significance, the absolute identity of ultraconserved elements has prompted speculation that these DNA sequences encode multiple critical functions (3). This principle raises the question of whether the ultraconserved region of the AUF1 gene containing exon 9 may be multifunctional. Supporting this model are observations that this region of the AUF1 gene is involved in the control of AUF1 splice variant expression by NMD and AMD (57; this paper). Additionally, bioinformatic analyses suggest that exon 9 may be a target for selected microRNAs (L. Banihashemi, S. Adusumalli, and G. Brewer, unpublished observations), presenting the possibility that microRNAs might act in concert with AMD and/or NMD, thereby contributing to processes dictating temporal, hormonal, or developmental expression patterns of AUF1 3'-UTR splice variants.
In this work, we observed dynamic expression of AUF1 3'-UTR splice variants during murine embryogenesis (Fig. 8), since levels of both NMD-sensitive mRNA variants (II and III) increased as embryogenesis proceeded. By contrast, levels of the NMD-insensitive splice variant I were unchanged across the developmental profile. These observations suggest that combinations of alternative pre-mRNA splicing, AMD, and NMD may be modulated during development and may contribute to stage-specific changes in the distribution of AUF1 3'-UTR variant mRNAs. Future experiments will explore the cause-and-effect relationships between NMD and dynamic expression of AUF1 3'-UTR splice variants during embryogenesis. Currently, these studies are hampered by observations that Upf1/Rent1/ mice are embryonically lethal (45). However, it might be informative to examine the effects of targeted AUF1 3'-UTR knockouts on embryogenesis and the ability of embryonic stem (ES) cells to commit to different cell lineages following administration of appropriate stimuli. A related issue is whether specific 3'-UTR structures might be coupled to an open reading frame encoding a particular protein isoform, since the selective inclusion or exclusion of exons 2 and 7 dictates which of the four AUF1 protein isoforms are synthesized (13, 30, 54). Resolution of this problem will be challenging, however, given that the four potential splicing variants of the coding region, each linked to any of five potential 3'-UTR variants, may yield as many as 20 different mRNA structures.
The work of Dietz and colleagues indicates that NMD controls the expression of several hundred native transcripts in mammalian cells, encoding proteins responsible for a broad array of biochemical functions (47). To our knowledge, however, the current study demonstrating the regulation of AUF1 3'-UTR splice variant expression by Upf1 and Upf2 provides the first mechanistic link between the NMD and AMD pathways. By regulating AUF1 expression, the population of genes and biochemical pathways subject to control by NMD would be dramatically enlarged through a combination of direct and indirect effects (Fig. 9). For example, as an AMD factor, AUF1 promotes the decay of mRNAs encoding proteins involved in cell growth, apoptosis, and signaling (34, 35). Moreover, the AUF1 protein isoforms are multifunctional and are known to regulate the transcription of several genes (12, 14, 20, 26, 53) as well as to contribute to telomere maintenance through interaction with telomere repeats (18). Interestingly, a link between NMD and telomere maintenance via regulation of RNA-binding proteins has already been reported for simple eukaryotes. In S. cerevisiae, EST1 encodes an RNA-binding protein with structural homology to AUF1 (18). The yeast NMD pathway regulates several genes involved in modulating telomerase activity, including EST1, EST2, EST3, and STN1 (17). Moreover, the human homologue of Est1p, termed hEST1A, is similar to SMG5 and SMG7a, which are Caenorhabditis elegans gene products involved in NMD (17).
![]() View larger version (27K): [in a new window] |
FIG. 9. Model for regulation of AUF1 expression and possible downstream pathways by NMD. NMD was first described as a mechanism to prevent the synthesis of truncated proteins by degrading mRNAs containing PTCs. Emerging models indicate that NMD may also regulate a variety of naturally occurring mRNAs, including AUF1 mRNA, as demonstrated in the current work. By controlling the production of cellular AUF1, NMD may thus indirectly influence a broad variety of biological pathways regulated through the various AUF1 isoforms, including telomere maintenance, cell growth, extracellular and intracellular signaling, and possibly many others. This model is discussed further in the text.
|
3' helicase activity following Upf1 knockdown, since ectopic expression of the Upf1 R844C mutant, which lacks helicase activity (52), resulted in twofold more luciferase expression from the Ex9:In9 reporter without significantly changing the mRNA level (Fig. 4). Accordingly, enhancement of luciferase-AUF1 Ex8:In9 translation through Upf1 is more likely mediated by some other function of the protein, such as direct RNA binding or RNA/DNA-dependent ATPase activity. Alternatively, the effect on translation of the Ex9:In9 reporter might be indirect. For example, Upf1 reduction could influence the expression of an unknown factor that is required to maintain translation of the Ex9:In9 reporter at normal levels. Future studies will address these possibilities and determine whether specific sequence elements within the AUF1 3'-UTR are required for Upf1-dependent changes in Ex9:In9 reporter translation. In conclusion, we have identified the AUF1/HNRPD gene as a native target of NMD, thus providing a mechanistic link between the AMD and NMD pathways. The plethora of potential mRNA variants derived from the combination of five possible 3'-UTR structures linked to four alternate open reading frames provides abundant regulatory possibilities for developmental and tissue-specific expression of AUF1 protein isoforms. This, in turn, could have profound consequences for a broad range of biochemical processes, including transcriptional and posttranscriptional control of gene expression, both intracellular and extracellular signaling, and telomere maintenance.
This work was supported by Public Health Service grants CA052443 (to G.B.) and CA102428 (to G.M.W.) from the National Institutes of Health.
Published ahead of print on 25 September 2006. ![]()
Supplemental material for this article may be found at http://mcb.asm.org/. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»